WDAF-TV

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms ...
Business Wire

Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new ...
Healio

Genomic test predicts metastasis risk after squamous cell carcinoma diagnosis

DecisionDx-SCC, a gene expression profile test, predicted individual risk for metastasis after a squamous cell carcinoma ...
Cure Today

DecisionDx-SCC Test Helps Predict Outcomes in High-Risk Skin Cancer

DecisionDx-SCC may help doctors more accurately guide treatment in high-risk cutaneous squamous cell carcinoma, the second most common form of skin cancer. New research suggests that a diagnostic test ...
Business Wire

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from UTILISE ...
Hosted on MSN

Castle Biosciences announces publication of two studies on DecisionDx-SCC test

Castle Biosciences (CSTL) announced the publication of two new studies related to its DecisionDx-SCC test, adding to its validated uses for patients with high-risk cutaneous squamous cell carcinoma.